Clinical Trial Update: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) [Phase 2, Phase 3]

View source ↗

Summary

A status update that RGX-202 gene therapy for Duchenne Muscular Dystrophy is in Phase 2/3 and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• RGX-202

Snippet

Sponsor: REGENXBIO Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 2, Phase 3 | Status: RECRUITING